{"title":"Deterministic, Threshold and Scenario Analyses","markdown":{"yaml":{"title":"Deterministic, Threshold and Scenario Analyses","format":{"revealjs":{"theme":"slides.scss","incremental":true,"slide-number":true,"logo":"../vchem.png","html-math-method":"katex","transition":"fade","background-transition":"fade","highlight-style":"ayu-mirage","footer":"[Back to Website](../index.html)\n"}},"editor_options":{"chunk_output_type":"console"},"editor":{"markdown":{"wrap":72}}},"headingText":"Learning Objectives and Outline","containsRefs":false,"markdown":"\n\n\n## Learning Objectives\n\n-   Explain the purpose of deterministic sensitivity analysis and\n    provide examples of one-way versus two-way analyses.\n\n-   Detail the advantages/disadvantages of deterministic sensitivity\n    analysis.\n\n## Outline\n\n1.  Net Benefit Outcome Measures\n2.  One-way sensitivity analysis.\n3.  Two-way sensitivity analysis.\n4.  Limitations and extensions.\n5.  Threshold analysis\n6.  Scenario analysis\n\n## Alternatives to ICERs\n\n-   ICERs the most common approach for describing CEA results\n    -   [Good]{style=\"color:green\"}: summarize all aspects of decision\n        problem except WTP (which comes from decision-maker)\n    -   [Bad]{style=\"color:red\"}: algorithms a bit complicated, negative\n        ICERs, ratios can act poorly when denominator uncertain\n\n## An Alternative\n\n-   If willing to choose a fixed willingness-to-pay threshold (e.g.,\n    $\\lambda =$ 100,000 / QALY), can write down an equation for the\n    contribution of health and cost to utility.\n    -   Net Health Benefit (NHB)\n    -   Net Monetary Benefit (NMB)\n-   [Objective]{style=\"color:blue\"}: Select the strategy with the\n    highest NHB/NMB\n\n## Net Health Benefit (NHB)\n\n$$\n\\text{NHB}_s = E_s - \\frac{C_s}{\\lambda}\n$$ where $E_s$ is effectiveness of strategy $s$, $C_s$ is cost of $s$\nand $\\lambda$ is WTP threshold.\n\n## Net Health Benefit (NHB)\n\n$$\n\\text{NMB}_s = E_s \\times \\lambda - C_s\n$$ where $E_s$ is effectiveness of strategy $s$, $C_s$ is cost of $s$\nand $\\lambda$ is WTP threshold.\n\n## Example: NHB\n\n::: columns\n::: column\n$E_1$ = 0.07 years\n\n$E_2$ = 0.10 years\n\n$C_1$ = 1,500\n\n$C_2$ = 2,800\n\n$\\lambda$ = 50,000 per year of life saved\n:::\n\n::: column\n$$\nICER = \\frac{2800-1500}{0.10 - 0.07}  \\\\\n= 43,333 \\\\\n$$\n:::\n:::\n\n## Example: NHB\n\n$$\nNHB_1 = 0.07 - 1500/50000 = 0.040 \\\\\nNHB_2 = 0.10 - 2800/50000 = 0.044\n\\\\\n\\text{Incremental } NHB = 0.044 - 0.040 = 0.004\n$$\n\n## Example: Net Monetary Benefit (NMB)\n\n$$\nNHB_1 = 0.07 \\times 50000 - 1500 = 2000 \\\\\nNHB_2 = 0.10 \\times 50000 - 2800 = 2200\n\\\\\n\\text{Incremental } NHB = 2200 - 2000 = 200\n$$\n\n## Calculating NMB in Amua\n\n::: r-stack\n![](images/clipboard-1972470218.png){.fragment width=\"750\" height=\"500\"}\n\n![](images/clipboard-2080375502.png){.fragment width=\"750\" height=\"500\"}\n\n![](images/clipboard-975167616.png){.fragment width=\"550\" height=\"300\"}\n\n![](images/clipboard-3987091812.png){.fragment width=\"550\" height=\"300\"}\n:::\n\n## Sensitivity\n\n-   ICER for Prevention strategy is just above WTP threshold of\n    \\$50,000/QALY.\n-   NMB for treatment only slightly above NMB for prevention.\n-   How sensitive are these results to changes in specific model inputs?\n\n# One-way sensitivity analysis {background=\"#43464B\"}\n\n## One-way sensitivity analysis\n\n::: incremental\n-   Usually the starting point for sensitivity analyses\n-   Sequentially testing one variable at a time (i.e., Age, BMI, QALY,\n    other clinically important parameters), while holding everything\n    else constant\n-   Determining how this variation impacts the results\n-   One-way sensitivity analyses are often presented in a **tornado\n    diagram**\n    -   Used to visually rank the different variables in order of their\n        overall influence on the magnitude of the model outputs\n:::\n\n# Examples from publications\n\n## Rotavirus study\n\n![](images/file_show.jpeg)\n\n## Rotavirus study\n\n![](images/file_show2.jpeg)\n\n## Rotavirus study\n\n![](images/file_show3.jpeg)\n\n## Other examples\n\n![](images/Screen%20Shot%202022-09-26%20at%2010.33.51%20PM.png)\n\n## Other examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.13.02%20AM-01.png)\n\n## Other examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.15.55%20AM.png){width=\"759\"}\n\n## Other examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.19.09%20AM.png){width=\"777\"}\n\n# Interactive Amua Session {background=\"#43464B\"}\n\n## Primary Results: Progressive Disease\n\n| Strategy   | ICER    |\n|------------|---------|\n| Status Quo | \\-      |\n| Treatment  | 49,513  |\n| Prevention | 139,630 |\n\n-   Treatment is cost-effective at WTP=\\$50,000/QALY---but *barely.*\n\n-   How sensitive is this result to the input parameter values used?\n\n# Two-way sensitivity analysis {background=\"#43464B\"}\n\n## Two-way sensitivity analysis\n\n::: incremental\n-   A way to map the interaction effects between two parameters in a\n    decision analysis model\n-   Varies 2 parameters at a time\n-   Explores the robustness of results in more depth\n:::\n\n# Examples from publications\n\n## HIV prevention\n\n![](images/Screen%20Shot%202022-09-28%20at%209.54.01%20AM.png){width=\"517\"}\n\n## HIV prevention\n\n::: incremental\n-   Markov model examining strategies for HIV prevention among\n    serodiscordant couples seeking conception (woman does not have HIV\n    and male has HIV)\n\n-   We know that if the **male partner is consistently on medication for\n    HIV** (i.e., resulting in virologic suppression), then the risk of\n    transmission is small regardless of the woman taking PrEP\n    (pre-exposure prophylaxis)\n\n-   And we also know that PrEP has traditionally been really **costly**\n:::\n\n## HIV prevention\n\n![](images/Screen%20Shot%202022-09-26%20at%2010.22.19%20PM.png)\n\n## Financial incentives for acute stroke care\n\n![](images/Screen%20Shot%202022-09-28%20at%2010.25.53%20PM.png){width=\"543\"}\n\n## Financial incentives for acute stroke care\n\n::: incremental\n-   Under pay for performance policies in the US, **physicians or\n    hospitals are paid more for meeting evidence-based quality targets**\n\n-   Study objective: Illustrate how pay-for-performance incentives can\n    be quantitatively bounded using cost-effectiveness modeling, through\n    the **application of reimbursement to hospitals for faster\n    time-to-tPA for acute ischemic stroke**\n:::\n\n## Financial incentives for acute stroke care\n\n> When administered quickly after stroke onset (within three hours, as\n> approved by the FDA), tPA helps to restore blood flow to brain regions\n> affected by a stroke, thereby limiting the risk of damage and\n> functional impairment\n\n## Financial incentives for acute stroke care\n\n![](images/Screen%20Shot%202022-09-28%20at%2010.14.03%20PM.png){width=\"520\"}\n\n# Interactive Amua Session {background=\"#43464B\"}\n\n# Limitations of deterministic sensitivity analyses {background=\"#43464B\"}\n\n## Caution: Limitations!\n\n-   Limited by the subjectivity of the choice of parameters to analyze\n-   That's why we also run PSAs!, i.e., varying ALL input parameters at\n    the same time, using priors to play a distribution around each value\n\n# Scenario analysis\n\n## Motivation\n\n-   Suppose we wanted to model the impact of these interventions under a\n    \"lower cost\" scenario.\n-   One option is to\n-   It may be more efficient to define different scenarios rather than\n    add additional strategies to the model structure itself.\n\n## Scenario analysis\n\n-   Focuses more on model **assumptions** rather than parameter\n    uncertainty\n-   Could include separate analysis on:\n\n> Subgroups/sub-populations, including different age cohorts & risk\n> levels\n\n<br>\n\n> Different perspectives (societal; modified societal; etc)\n\n## Scenario analysis\n\n> Hypothetical scenarios (\"optimistic\" and \"conservative\" scenarios; for\n> example, if we have little evidence of long-term survival associated\n> with medication X, we might have an optimistic versus conservative\n> scenario)\n\n<br>\n\n> Time horizons\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.13.02%20AM-02.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.25.20%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.25.50%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.26.44%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%208.54.33%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.11.39%20AM.png){width=\"748\"}\n\n# Threshold analysis\n\n## Threshold analysis\n\n-   Answers the question: What the input parameter need be to meet the\n    country thresholds of:\n    -   \\$50,000/QALY gained\n    -   \\$100,000/QALY gained\n    -   \\$150,000/QALY gained\n    -   \\$200,000/QALY gained\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.13.02%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.14.02%20AM.png)\n\n# Thank you!\n","srcMarkdownNoYaml":"\n\n# Learning Objectives and Outline\n\n## Learning Objectives\n\n-   Explain the purpose of deterministic sensitivity analysis and\n    provide examples of one-way versus two-way analyses.\n\n-   Detail the advantages/disadvantages of deterministic sensitivity\n    analysis.\n\n## Outline\n\n1.  Net Benefit Outcome Measures\n2.  One-way sensitivity analysis.\n3.  Two-way sensitivity analysis.\n4.  Limitations and extensions.\n5.  Threshold analysis\n6.  Scenario analysis\n\n## Alternatives to ICERs\n\n-   ICERs the most common approach for describing CEA results\n    -   [Good]{style=\"color:green\"}: summarize all aspects of decision\n        problem except WTP (which comes from decision-maker)\n    -   [Bad]{style=\"color:red\"}: algorithms a bit complicated, negative\n        ICERs, ratios can act poorly when denominator uncertain\n\n## An Alternative\n\n-   If willing to choose a fixed willingness-to-pay threshold (e.g.,\n    $\\lambda =$ 100,000 / QALY), can write down an equation for the\n    contribution of health and cost to utility.\n    -   Net Health Benefit (NHB)\n    -   Net Monetary Benefit (NMB)\n-   [Objective]{style=\"color:blue\"}: Select the strategy with the\n    highest NHB/NMB\n\n## Net Health Benefit (NHB)\n\n$$\n\\text{NHB}_s = E_s - \\frac{C_s}{\\lambda}\n$$ where $E_s$ is effectiveness of strategy $s$, $C_s$ is cost of $s$\nand $\\lambda$ is WTP threshold.\n\n## Net Health Benefit (NHB)\n\n$$\n\\text{NMB}_s = E_s \\times \\lambda - C_s\n$$ where $E_s$ is effectiveness of strategy $s$, $C_s$ is cost of $s$\nand $\\lambda$ is WTP threshold.\n\n## Example: NHB\n\n::: columns\n::: column\n$E_1$ = 0.07 years\n\n$E_2$ = 0.10 years\n\n$C_1$ = 1,500\n\n$C_2$ = 2,800\n\n$\\lambda$ = 50,000 per year of life saved\n:::\n\n::: column\n$$\nICER = \\frac{2800-1500}{0.10 - 0.07}  \\\\\n= 43,333 \\\\\n$$\n:::\n:::\n\n## Example: NHB\n\n$$\nNHB_1 = 0.07 - 1500/50000 = 0.040 \\\\\nNHB_2 = 0.10 - 2800/50000 = 0.044\n\\\\\n\\text{Incremental } NHB = 0.044 - 0.040 = 0.004\n$$\n\n## Example: Net Monetary Benefit (NMB)\n\n$$\nNHB_1 = 0.07 \\times 50000 - 1500 = 2000 \\\\\nNHB_2 = 0.10 \\times 50000 - 2800 = 2200\n\\\\\n\\text{Incremental } NHB = 2200 - 2000 = 200\n$$\n\n## Calculating NMB in Amua\n\n::: r-stack\n![](images/clipboard-1972470218.png){.fragment width=\"750\" height=\"500\"}\n\n![](images/clipboard-2080375502.png){.fragment width=\"750\" height=\"500\"}\n\n![](images/clipboard-975167616.png){.fragment width=\"550\" height=\"300\"}\n\n![](images/clipboard-3987091812.png){.fragment width=\"550\" height=\"300\"}\n:::\n\n## Sensitivity\n\n-   ICER for Prevention strategy is just above WTP threshold of\n    \\$50,000/QALY.\n-   NMB for treatment only slightly above NMB for prevention.\n-   How sensitive are these results to changes in specific model inputs?\n\n# One-way sensitivity analysis {background=\"#43464B\"}\n\n## One-way sensitivity analysis\n\n::: incremental\n-   Usually the starting point for sensitivity analyses\n-   Sequentially testing one variable at a time (i.e., Age, BMI, QALY,\n    other clinically important parameters), while holding everything\n    else constant\n-   Determining how this variation impacts the results\n-   One-way sensitivity analyses are often presented in a **tornado\n    diagram**\n    -   Used to visually rank the different variables in order of their\n        overall influence on the magnitude of the model outputs\n:::\n\n# Examples from publications\n\n## Rotavirus study\n\n![](images/file_show.jpeg)\n\n## Rotavirus study\n\n![](images/file_show2.jpeg)\n\n## Rotavirus study\n\n![](images/file_show3.jpeg)\n\n## Other examples\n\n![](images/Screen%20Shot%202022-09-26%20at%2010.33.51%20PM.png)\n\n## Other examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.13.02%20AM-01.png)\n\n## Other examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.15.55%20AM.png){width=\"759\"}\n\n## Other examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.19.09%20AM.png){width=\"777\"}\n\n# Interactive Amua Session {background=\"#43464B\"}\n\n## Primary Results: Progressive Disease\n\n| Strategy   | ICER    |\n|------------|---------|\n| Status Quo | \\-      |\n| Treatment  | 49,513  |\n| Prevention | 139,630 |\n\n-   Treatment is cost-effective at WTP=\\$50,000/QALY---but *barely.*\n\n-   How sensitive is this result to the input parameter values used?\n\n# Two-way sensitivity analysis {background=\"#43464B\"}\n\n## Two-way sensitivity analysis\n\n::: incremental\n-   A way to map the interaction effects between two parameters in a\n    decision analysis model\n-   Varies 2 parameters at a time\n-   Explores the robustness of results in more depth\n:::\n\n# Examples from publications\n\n## HIV prevention\n\n![](images/Screen%20Shot%202022-09-28%20at%209.54.01%20AM.png){width=\"517\"}\n\n## HIV prevention\n\n::: incremental\n-   Markov model examining strategies for HIV prevention among\n    serodiscordant couples seeking conception (woman does not have HIV\n    and male has HIV)\n\n-   We know that if the **male partner is consistently on medication for\n    HIV** (i.e., resulting in virologic suppression), then the risk of\n    transmission is small regardless of the woman taking PrEP\n    (pre-exposure prophylaxis)\n\n-   And we also know that PrEP has traditionally been really **costly**\n:::\n\n## HIV prevention\n\n![](images/Screen%20Shot%202022-09-26%20at%2010.22.19%20PM.png)\n\n## Financial incentives for acute stroke care\n\n![](images/Screen%20Shot%202022-09-28%20at%2010.25.53%20PM.png){width=\"543\"}\n\n## Financial incentives for acute stroke care\n\n::: incremental\n-   Under pay for performance policies in the US, **physicians or\n    hospitals are paid more for meeting evidence-based quality targets**\n\n-   Study objective: Illustrate how pay-for-performance incentives can\n    be quantitatively bounded using cost-effectiveness modeling, through\n    the **application of reimbursement to hospitals for faster\n    time-to-tPA for acute ischemic stroke**\n:::\n\n## Financial incentives for acute stroke care\n\n> When administered quickly after stroke onset (within three hours, as\n> approved by the FDA), tPA helps to restore blood flow to brain regions\n> affected by a stroke, thereby limiting the risk of damage and\n> functional impairment\n\n## Financial incentives for acute stroke care\n\n![](images/Screen%20Shot%202022-09-28%20at%2010.14.03%20PM.png){width=\"520\"}\n\n# Interactive Amua Session {background=\"#43464B\"}\n\n# Limitations of deterministic sensitivity analyses {background=\"#43464B\"}\n\n## Caution: Limitations!\n\n-   Limited by the subjectivity of the choice of parameters to analyze\n-   That's why we also run PSAs!, i.e., varying ALL input parameters at\n    the same time, using priors to play a distribution around each value\n\n# Scenario analysis\n\n## Motivation\n\n-   Suppose we wanted to model the impact of these interventions under a\n    \"lower cost\" scenario.\n-   One option is to\n-   It may be more efficient to define different scenarios rather than\n    add additional strategies to the model structure itself.\n\n## Scenario analysis\n\n-   Focuses more on model **assumptions** rather than parameter\n    uncertainty\n-   Could include separate analysis on:\n\n> Subgroups/sub-populations, including different age cohorts & risk\n> levels\n\n<br>\n\n> Different perspectives (societal; modified societal; etc)\n\n## Scenario analysis\n\n> Hypothetical scenarios (\"optimistic\" and \"conservative\" scenarios; for\n> example, if we have little evidence of long-term survival associated\n> with medication X, we might have an optimistic versus conservative\n> scenario)\n\n<br>\n\n> Time horizons\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.13.02%20AM-02.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.25.20%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.25.50%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.26.44%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%208.54.33%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.11.39%20AM.png){width=\"748\"}\n\n# Threshold analysis\n\n## Threshold analysis\n\n-   Answers the question: What the input parameter need be to meet the\n    country thresholds of:\n    -   \\$50,000/QALY gained\n    -   \\$100,000/QALY gained\n    -   \\$150,000/QALY gained\n    -   \\$200,000/QALY gained\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.13.02%20AM.png)\n\n## Examples\n\n![](images/Screen%20Shot%202022-10-06%20at%209.14.02%20AM.png)\n\n# Thank you!\n"},"formats":{"revealjs":{"identifier":{"display-name":"RevealJS","target-format":"revealjs","base-format":"revealjs"},"execute":{"fig-width":10,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":true,"echo":false,"output":true,"warning":false,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":null,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"ipynb-shell-interactivity":null,"plotly-connected":true,"engine":"markdown"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":true,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-min-runs":1,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[]},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","html-math-method":"katex","slide-level":2,"to":"revealjs","incremental":true,"highlight-style":"ayu-mirage","output-file":"lec_sensitivity.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","appendix-view-license":"View License","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","tools-share":"Share","tools-download":"Download","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-text-placeholder":"","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words","listing-page-filter":"Filter","draft":"Draft"},"metadata":{"lang":"en","fig-responsive":false,"quarto-version":"1.8.24","auto-stretch":true,"title":"Deterministic, Threshold and Scenario Analyses","editor_options":{"chunk_output_type":"console"},"editor":{"markdown":{"wrap":72}},"theme":"slides.scss","slideNumber":true,"logo":"../vchem.png","transition":"fade","backgroundTransition":"fade","footer":"[Back to Website](../index.html)\n"}}},"projectFormats":["html"]}